Table 2.

Summary of CAR-T cells co-expressing non-cytokines in the treatment of tumors

Non-cytokine based cargos	Tumor	Targeted antigen	Model	Reference
PD-1-blocking scFv	ovarian carcinoma	CD19, MUC16	immune-deficient/competent tumor model	Rafiq et al.85
Anti-PD-L1 antibody	renal cell carcinoma	CAIX	immune-deficient tumor model	Suarez et al.86
HPSE	neuroblastoma	GD2	immune-deficient tumor model	Caruana et al.89
Drug activating enzymes	leukemia	CD19	immune-deficient/competent tumor model	Gardner et al.92
Neutrophil-activating protein from Hp.	lymphoma and neuroblastoma	CD19, GD2	immune-competent tumor model	Jin et al.51
12 co-stimulatory receptors	B cell lymphomas	CD20	immune-deficient tumor model	Zhang et al.99
Anti-CD38 CCR	multiple myeloma	BCMA, CD19	immune-deficient/competent tumor model	Katsarou et al.100
Anti-B7-H3 CCR	neuroblastoma	GD2	immune-deficient tumor model	Hirabayashi et al.101
PD-L1-specific CSR	chronic myeloid leukemia and lung cancer	CD19, MSLN	immune-deficient tumor model	Qin et al.102
TBBR	prostate cancer	PSCA	immune-deficient tumor model	Sukumaran et al.103
Anti-PSMA CCR	prostate cancer	PSCA	immune-deficient tumor model	Kloss et al.105
c-Jun	neuroblastoma	GPC-2	immune-deficient tumor model	Heitzeneder et al.111